NEW YORK, Feb. 22, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced an
update on its broad spectrum anti-viral platform compounds with the
potential to treat influenza, COVID-19, Ebola and other
viral infections. The initial two lead compounds, which
target the SKI complex in humans, have been optimized through the
use of computer assisted learning, through two rounds of chemical
modifications to achieve drug-like properties required to move the
compounds into animal testing. In addition, a third lead
compound has been identified and will be subjected to optimization.
These new compounds are currently being tested against Influenza
virus with testing on SARS-CoV-2 in the near future.
Subsequently, the top analogs from each series of
lead compounds will be selected for tests of their anti-viral
effects in a SARS-CoV-2 mouse model.
Anthony Hayes, CEO of AIkido
Pharma, stated, "We are excited to be using Artificial Intelligence
technology to advance the development of these compounds and proud
to announce these advancements in the research."
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers and we are currently in the process of
developing an innovative therapeutic drug platform through strong
partnerships with world renowned educational institutions,
including The University of Texas at Austin and Wake Forest
University. Our diverse pipeline of therapeutics includes therapies
for pancreatic cancer, acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
Investor
Relations:
|
|
|
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
|
|
AIkido Pharma
Inc.:
|
|
|
|
Phone:
212-745-1373
|
|
Email:
investorrelations@aikidopharma.com
|
|
www.aikidopharma.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-provides-update-on-its-antiviral-platform-including-the-virus-that-causes-covid-19-301231899.html
SOURCE AIkido Pharma Inc.